PedAM
Pediatric Disease Annotations & Medicines
| Disease | c syndrome |
| Phenotype | C0282193|iron overload |
| Sentences | 23 |
| PubMedID- 26576280 | iron overload-related heart failure in a patient with transfusion-dependent myelodysplastic syndrome reversed by intensive combined chelation therapy. |
| PubMedID- 23937987 | A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes. |
| PubMedID- 23766520 | Increased parameters of oxidative stress and its relation to transfusion iron overload in patients with myelodysplastic syndromes. |
| PubMedID- 22829233 | Clearly elevated cardiac r2(*) was found in two myelodysplastic syndrome (mds) patients with severe liver iron overload. |
| PubMedID- 19719471 | Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices. |
| PubMedID- 25516455 | Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications. |
| PubMedID- 21822196 | iron overload in patients with transfusion dependent myelodisplastic syndrome. |
| PubMedID- 22338168 | [pay great attention to the diagnosis and treatment of iron overload in myelodysplastic syndromes]. |
| PubMedID- 22924125 | Health-related quality of life, treatment satisfaction, adherence and persistence in beta-thalassemia and myelodysplastic syndrome patients with iron overload receiving deferasirox: results from the epic clinical trial. |
| PubMedID- 23628060 | [current understanding of iron overload hazard in patients with myelodysplastic syndrome]. |
| PubMedID- 19903678 | Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a gitmo study. |
| PubMedID- 26453076 | Can iron overload in patients with lower-risk myelodysplastic syndromes be reduced using erythropoiesis-stimulating agents. |
| PubMedID- 22890139 | Two patients were undergoing phlebotomy and had no iron overload, 1 with metabolic syndrome and no phlebotomy had mild iron overload, and 2 patients had severe iron overload despite phlebotomy. |
| PubMedID- 25743685 | Overall, about 760 myelodysplastic syndrome (mds) patients with iron overload receiving deferasirox were included in six different studies, and an increase in hemoglobin level was reported to range from 6 to 44.5%, an increase in platelet count from 13 to 61%, and in neutrophil count from 3 to 76%. |
| PubMedID- 26224043 | Background: hepatic iron overload is common in patients with myelodysplastic syndromes undergoing hematopoietic cell transplantation (hct) and may predispose to peri- and post-hct toxicity. |
| PubMedID- 24598841 | Dysregulation of hepcidin, a key iron regulating hormone, is important in the pathogenesis of iron overload in patients with myelodysplatic syndrome (mds). |
| PubMedID- 25764148 | Deferasirox (dfx) is an orally administered iron chelator approved for use in patients with transfusion-dependent iron overload due to myelodysplastic syndromes (mds). |
| PubMedID- 20332502 | iron overload in myelodysplastic syndromes. |
| PubMedID- 23086508 | Transfusion therapy in the treatment of patients with blood disorders such as β-thalassemia major, sickle cell disease (scd), and myelodysplastic syndromes (mds) rapidly leads to iron overload and subsequent tissue and organ damage unless effective chelation therapy is used to control tissue iron levels [9, 10]. |
| PubMedID- 20125080 | iron overload in myelodysplastic syndromes: diagnosis and management. |
| PubMedID- 21069694 | Deferasirox for managing iron overload in people with myelodysplastic syndrome. |
| PubMedID- 25348770 | Objectives: to evaluate the effectiveness and safety of oral deferasirox for managing iron overload in people with myelodysplastic syndrome (mds). |
| PubMedID- 25672910 | Certain characteristics of metabolic syndrome are mainly attributed to iron overload (20). |
Page: 1